FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Lush

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
MICHELLE RUDEK-RENAUT; Kenneth S. Bauer; Richard M Lush; Sherman F Stinson; Adrian M Senderowicz; Donna Headlee; Arbuck Susan; Michael C Cox; Anthony J Murgo; Edward A Sausville; William D Figg
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
Edward A Sausville; Arbuck Susan; Richard A Messmann; Donna Headlee; Kenneth S. Bauer; Richard M Lush; Anthony J Murgo; William D Figg; Tyler Lahusen; S Jaken; X Jing ; M Roberge; Eiichi Fuse; Takashi Kuwabara; Adrian M Senderowicz
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Jean L Grem; Mary Quinn; Abdel-Salam Attia Ismail; Chris H Takimoto; Richard M Lush; David J Liewehr; Seth M Steinberg; FRANK BALIS; Alice P Chen; Brian P Monahan; Nancy Harold; W Corse; Janet Pang; RF Murphy; Carmen J Allegra; J Michael Hamilton
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Lush (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: MICHELLE RUDEK-RENAUT; Kenneth S. Bauer; Richard M Lush; Sherman F Stinson; Adrian M Senderowicz; Donna Headlee; Arbuck Susan; Michael C Cox; Anthony J Murgo; Edward A Sausville; William D Figg
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
The Annals of pharmacotherapy 2003;37(10):1369-74.
2001: Edward A Sausville; Arbuck Susan; Richard A Messmann; Donna Headlee; Kenneth S. Bauer; Richard M Lush; Anthony J Murgo; William D Figg; Tyler Lahusen; S Jaken; X Jing ; M Roberge; Eiichi Fuse; Takashi Kuwabara; Adrian M Senderowicz
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2319-33.
2001: Jean L Grem; Mary Quinn; Abdel-Salam Attia Ismail; Chris H Takimoto; Richard M Lush; David J Liewehr; Seth M Steinberg; FRANK BALIS; Alice P Chen; Brian P Monahan; Nancy Harold; W Corse; Janet Pang; RF Murphy; Carmen J Allegra; J Michael Hamilton
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.
Cancer chemotherapy and pharmacology 2001;47(2):117-25.
2000: Kenneth S. Bauer; Richard M Lush; MICHELLE RUDEK-RENAUT; C Shih; Edward A Sausville; William D Figg
A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.
Biomedical chromatography : BMC 2000;14(5):338-43.
1999: H K Cho; Richard M Lush; David L Bartlett; H Richard Alexander; Peter C Wu; Steven Libutti; KB Lee; David J Venzon; Kenneth S. Bauer; Eddie Reed; William D Figg
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
Journal of clinical pharmacology 1999;39(4):394-401.
1999: Adrian M Senderowicz; R Reid; Donna Headlee; T Abornathy; J Horti; Richard M Lush; Eddie Reed; William D Figg; Edward A Sausville
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
Urologia internationalis 1999;63(2):120-5.
1998: Kenneth S. Bauer; Elise C Kohn; Richard M Lush; Seth M Steinberg; P Davis; David R Kohler; Eddie Reed; William D Figg
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
Journal of pharmacokinetics and biopharmaceutics 1998;26(6):673-87.
1998: Adrian M Senderowicz; Donna Headlee; Sherman F Stinson; Richard M Lush; N Kalil; L Villalba; K Hill; Seth M Steinberg; William D Figg; AC Tompkins; Arbuck Susan; Edward A Sausville
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):2986-99.
1998: Lauri Welles; MW Saville; JA Lietzau; James M Pluda; Kathleen M Wyvill; I Feuerstein; William D Figg; Richard M Lush; J Odom; Wyndham H Wilson; M T Fajardo; Rachel Humphrey; Ellen G Feigal; David Tuck; Seth M Steinberg; S Broder; Robert Yarchoan
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1112-21.
1998: J A Feuer; Richard M Lush; David Venzon; Paul H Duray; AC Tompkins; Oliver Sartor; William D Figg
Elevated carcinoembryonic antigen in patients with androgen-independent prostate cancer.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 1998;46(2):66-72.
1998: A Thibault; William D Figg; Raymond C Bergan; Richard M Lush; Charles E Myers; AC Tompkins; Eddie Reed; D Samid
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.
Tumori 1998;84(1):87-9.
1997: Adrian M Senderowicz; Ellen S Vitetta; Donna Headlee; Victor Ghetie; Jonathan Uhr; William D Figg; Richard M Lush; Maryalice Stetler-Stevenson; G Kershaw; Douglas W Kingma; Elaine S Jaffe; Edward A Sausville
Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
Annals of internal medicine 1997;126(11):882-5.
1997: Stephen C Piscitelli; A Forrest; Richard M Lush; N Ryan; L R Whitfield; William D Figg
Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
Pharmacotherapy 1997;17(3):431-7.
1997: G Y Ma; David L Bartlett; Eddie Reed; William D Figg; Richard M Lush; KB Lee; Steven Libutti; H Richard Alexander
Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
The cancer journal from Scientific American 1997;3(3):174-9.
1997: William D Figg; Michaele C Christian; Richard M Lush; Charles J. Link; P Davis; Elise C Kohn; Gisele Sarosy; M L Rothenberg; R B Weiss; N Ryan; J Jacobs; Eddie Reed
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Biopharmaceutics & drug disposition 1997;18(4):347-59.
1997: Shannon C Dixon; A Zalles; C Giordano; Richard M Lush; David Venzon; Eddie Reed; William D Figg
In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.
Cancer letters 1997;113(1-2):111-6.
1997: Richard M Lush; Beverly Meadows; Antonio Tito Fojo; G Kalafsky; H T Smith; Susan Bates; William D Figg
Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.
Journal of clinical pharmacology 1997;37(2):123-8.
1997: William D Figg; James M Pluda; Richard M Lush; MW Saville; Kathleen M Wyvill; Eddie Reed; Robert Yarchoan
The pharmacokinetics of TNP-470, a new angiogenesis inhibitor.
Pharmacotherapy 1997;17(1):91-7.
1997: Shannon C Dixon; B J Soriano; Richard M Lush; M M Borner; William D Figg
Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target.
The Annals of pharmacotherapy 1997;31(1):76-82.
1996: S Boudoulas; Richard M Lush; N A McCall; D Samid; E Reed; William D Figg
Plasma protein binding of phenylacetate and phenylbutyrate, two novel antineoplastic agents.
Therapeutic drug monitoring 1996;18(6):714-20.
1996: Richard M Lush; William D Figg; James M Pluda; R Bitton; Donna Headlee; David R Kohler; Eddie Reed; Oliver Sartor; MR Cooper
A phase I study of pentosan polysulfate sodium in patients with advanced malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(9):939-44.
1996: lee stone; Edward A Sausville; Joseph W Fay; Donna Headlee; Robert H Collins; William D Figg; Maryalice Stetler-Stevenson; V Jain; E S Jaffe; D Solomon; Richard M Lush; Adrian M Senderowicz; Victor Ghetie; J Schindler; J W Uhr; Ellen S Vitetta
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
Blood 1996;88(4):1188-97.
1996: Nancy A Dawson; Richard M Lush; Seth M Steinberg; AC Tompkins; Donna Headlee; William D Figg
Suramin-induced neutropenia.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1534-9.
1996: M N Middleman; Richard M Lush; William D Figg
The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
Pharmacotherapy 1996;16(3):376-81.
1996: M N Middleman; Richard M Lush; Oliver Sartor; Eddie Reed; William D Figg
Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.
Cancer treatment reviews 1996;22(2):105-18.
1996: William D Figg; Nancy A Dawson; M N Middleman; Otis W Brawley; Richard M Lush; Adrian M Senderowicz; S H Steinberg; AC Tompkins; Eddie Reed; Oliver Sartor
Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
Acta oncologica (Stockholm, Sweden) 1996;35(6):763-5.